Nebulizer

Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference

Retrieved on: 
Monday, March 1, 2021
Respiratory therapy, Health sciences, Health, Chronic lower respiratory diseases, Dosage forms, Chronic obstructive pulmonary disease, Nebulizer, Forward-looking statement

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 25, 2021
Health sciences, Medicine, Dosage forms, Clinical medicine, Respiratory therapy, Asthma, Dry-powder inhaler, Metered-dose inhaler, Inhaler, Respiratory disease, Nebulizer, Formoterol

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI).
  • Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases.
  • Verona Pharma has also implemented measures to help keep the Companys employees, families, and local communities healthy and safe.

With Monaghan Medical, Safe Nebulizer Therapy is Possible

Retrieved on: 
Tuesday, February 23, 2021
Health sciences, Respiratory therapy, Medicine, Medical equipment, Dosage forms, Health, Aerosols, Nebulizer, Severe acute respiratory syndrome

PLATTSBURGH, N.Y., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Monaghan Medical Corporation wants you to know that you can create a safer environment when delivering nebulizer therapy.

Key Points: 
  • PLATTSBURGH, N.Y., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Monaghan Medical Corporation wants you to know that you can create a safer environment when delivering nebulizer therapy.
  • Nebulizer therapy is a common treatment for many pulmonary respiratory conditions.
  • Monaghan Medicals Filtered Mouthpiece Kit provides assurance for caregivers assisting with nebulizer therapy, with a 99.997%3 viral and 99.9997%3 bacterial filtration efficiencies.
  • An informal online survey conducted by Monaghan Medical5 proved paramount in understanding why a Filtered Mouthpiece Kit is of extreme importance now with the SARS-Co-V2 pandemic.

Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Retrieved on: 
Thursday, February 18, 2021
Chronic lower respiratory diseases, Respiratory therapy, Medical specialties, Clinical medicine, Health, Nebulizer, Chronic obstructive pulmonary disease, Asthma, Respiratory disease, Cystic fibrosis, Obstructive lung disease

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • If successfully developed and approved, Verona Pharmas product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases.

InventHelp Inventor Develops Nebulizer Kit for Respiratory Emergencies (LAX-1228)

Retrieved on: 
Thursday, February 4, 2021
Health sciences, Aerosols, Dosage forms, Medical equipment, Respiratory therapy, Nebulizer, Health care, Patent, Health

My design offers an easier transition if the patient's condition becomes critical and it provides added peace of mind during stressful situations."

Key Points: 
  • My design offers an easier transition if the patient's condition becomes critical and it provides added peace of mind during stressful situations."
  • The patent-pending invention provides an improved nebulizer kit for treating hypoxic pediatric patients in emergency and critical care settings.
  • The original design was submitted to the Los Angeles sales office of InventHelp.
  • 19-LAX-1228, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Retrieved on: 
Tuesday, February 2, 2021
Health sciences, Dosage forms, Medicine, Clinical medicine, Respiratory therapy, Asthma, Chronic lower respiratory diseases, Aerosols, Nebulizer, Inhaler, Dry-powder inhaler, Cystic fibrosis

Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.

Key Points: 
  • Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.
  • Ensifentrine has demonstrated significant and clinically meaningful improvements in both lung function and symptoms, including breathlessness, in Verona Pharmas Phase 2 clinical studies in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI).

2020 Insights on the Global Respiratory Care Market to 2024 - Including Noninvasive Ventilation and Airway Management Products - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 26, 2021
Health, Medical devices, Other Health, Medicine, Clinical medicine, Medical specialties, Mechanical ventilation, Medical equipment, Intensive care medicine, Respiratory therapy, Non-invasive ventilation, Nebulizer, Continuous positive airway pressure, Positive airway pressure, Airway management

The "Respiratory Care: Noninvasive Ventilation and Airway Management Products" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Care: Noninvasive Ventilation and Airway Management Products" report has been added to ResearchAndMarkets.com's offering.
  • This report covers the global market including the US, five major European markets (France, Germany, Italy, Spain, and the UK) for 2019-24.
  • In 2019, combined global sales of the PAP-based NIV products and airway management accessories covered by this report totalled nearly $7bn, with NIV products accounting for more than two-thirds of total sales.
  • This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the positive airway pressure (PAP)-based noninvasive ventilation (NIV) and airway management products market, including CPAP and BiPAP devices as well as heat/moisture exchangers (HMEs), humidifiers, and nebulizers (including large- and small-volume nebulizers and nebulizer compressors).

Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

Retrieved on: 
Tuesday, January 5, 2021
Respiratory therapy, Health sciences, Health, Chronic lower respiratory diseases, Occupational diseases, Dosage forms, Chronic obstructive pulmonary disease, Nebulizer, Forward-looking statement

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Global Respiratory Inhaler Devices Market (2020 to 2025) - by Product, Technology, End-user, Disease Indication and Geography - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 29, 2020
Health, Pharmaceutical, Health sciences, Medicine, Respiratory therapy, Health, Dosage forms, Asthma, Inhaler, Coronavirus disease, Respiratory disease, Metered-dose inhaler, Nebulizer

The "Global Respiratory Inhaler Devices Market (2020-2025) by Product, Technology, End-User, Disease Indication and Geography and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Respiratory Inhaler Devices Market (2020-2025) by Product, Technology, End-User, Disease Indication and Geography and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • In 2020, global revenue generated by respiratory inhaler devices stood at USD 33 billion and is expected to reach USD 40 billion by 2025, growing at a CAGR of 6.9%.
  • Respiratory inhaler devices are medical devices that assist a patient with respiratory issues like asthma, COPD, and other respiratory disorder.
  • The growth of the market is attributed to higher demand in the near future due to the increasing number of patients with respiratory diseases.

Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin

Retrieved on: 
Tuesday, December 22, 2020
Medical specialties, Branches of biology, Gram-negative bacteria, Pseudomonadales, Clinical medicine, Cyclic peptides, Antibiotic-resistant bacteria, Pseudomonas aeruginosa, Murepavadin, Cystic fibrosis, Pseudomonas, Nebulizer

The Phase I study is part of the clinical development plan exploring the inhaled formulation of murepavadin to treat Pseudomonas aeruginosa infections in people with cystic fibrosis, including resistant bacterial strains.

Key Points: 
  • The Phase I study is part of the clinical development plan exploring the inhaled formulation of murepavadin to treat Pseudomonas aeruginosa infections in people with cystic fibrosis, including resistant bacterial strains.
  • The safety, tolerability, and pharmacokinetic study is using eFlow Technology nebulizer (PARI Pharma GmbH) to administer murepavadin Inhalation Solution (MIS) in healthy volunteers.
  • Polyphors inhaled murepavadin is currently being developed as a precision antibiotic specifically for the treatment of chronic Pseudomonas aeruginosa infections in people with CF.
  • Based on the data of the inhaled murepavadin preclinical program suggesting significantly higher safety margins (at least 5-10 times) versus the intravenous formulation, Polyphor is initiating a clinical development program in CF.